Want to join the conversation?
$PFE's research and development expenses for 2015 slid by 8% from last year. This decline was primarily due to non-recurrence of a charge associated with a collaborative arrangement with Merck, lower clinical trial expenses for various studies, lower upfront payments, and the favorable impact of foreign exchange of 2%.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.